Fractyl Labs touts 1-year data for Revita DMR in T2D patients

Fractyl Laboratories touted data today showing sustained improvement in glycemic parameters after one year following a single treatment with its Revita duodenal mucosal resurfacing system in patients with Type II diabetes.

“This is the first presentation of one-year data on the durability of the Revita DMR procedure in Type II diabetes. The Revita DMR procedure was well tolerated, and no serious adverse events related to the device or procedure were reported through one-year of follow up,” co-founder & CEO Dr. Harith Rajagopalan said in prepared remarks. “Additional data on the durability of this intervention’s effects on liver measures in patients with Type II diabetes will also be presented at AASLD later this year.”

Get the full story at our sister site, Drug Delivery Business News.

The post Fractyl Labs touts 1-year data for Revita DMR in T2D patients appeared first on MassDevice.

from MassDevice http://ift.tt/2w4HvDs